RDY:NYSE
Dr Reddy's Laboratories Ltd
$ 13.07
arrow_upward
+1.32%(+0.17) 1D
$ 13.07
0.00% (0.00)
bedtimeAfter hours
Closed: 10-р сарын 16, 16:00:07 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RDY...
Open
$ 13.00
High
$ 13.07
Low
$ 12.94
Mkt. cap
10.81 тэрбум
Avg. vol.
3.19 сая
Volume
2.79 сая
Dividend
0.64%
Quarterly dividend
$ 0.02
Ex-dividend date
2026 оны 7-р сарын 10
P/E ratio
31.34
52-wk high
$ 15.67
52-wk low
$ 11.36
EPS
$ 0.42
Beta
0.30
Shares outstanding
834.64 сая
No. of employees
28 мян
Open
$ 13.00
High
$ 13.07
Low
$ 12.94
Mkt. cap
10.81 тэрбум
Avg. vol.
3.19 сая
Volume
2.79 сая
Dividend
0.64%
Quarterly dividend
$ 0.02
Ex-dividend date
2026 оны 7-р сарын 10
P/E ratio
31.34
52-wk high
$ 15.67
52-wk low
$ 11.36
EPS
$ 0.42
Beta
0.30
Shares outstanding
834.64 сая
No. of employees
28 мян
News stories
From web sources and news partners
CNBC TV18
·
16 цагийн өмнө
Pharma Stocks: Macquarie sees margin pressure in Q2, upgrades Dr Reddy’s and Alkem
MarketBeat
·
20 цагийн өмнө
Dr. Reddy's Laboratories (RDY) Expected to Announce Quarterly Earnings on Friday
ad-hoc-news.de
·
1 өдрийн өмнө
Dr Reddy reports three FDA observations: what it means for Dr Reddy stock
TipRanks
·
2 өдрийн өмнө
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5 мян
Founded1984
HeadquartersХайдерабад, Андрапрадеш, Энэтхэг
SectorPharmaceutical industry
Websitedrreddys.com